The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated significant profits, the end of its exclusive rights opened the floodgates to generic https://neilrecq878986.atualblog.com/48507730/sildenafil-and-the-pharmaceutical-industry-a-risky-investment